{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:19:40Z","timestamp":1785615580944,"version":"3.56.0"},"reference-count":20,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s461771","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T02:35:16Z","timestamp":1718332516000},"page":"2273-2285","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3266-8765","authenticated-orcid":true,"given":"Wanjun","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1586\/1744666X.2016.1134319","volume":"12","author":"Chiricozzi","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","volume":"19","author":"Torres","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(19)31772-6","volume":"394","author":"Mahil","year":"2019","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-014-0218-4","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref9","unstructured":"FDA. Clinical pharmacology biopharmaceutics review(s). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205437Orig1s000ClinPharmR.pdf. Accessed November 21, 2013."},{"key":"ref10","unstructured":"FDA. M9 biopharmaceutics classification system-based biowaivers. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m9-biopharmaceutics-classification-system-based-biowaivers. Accessed June 10, 2024."},{"key":"ref11","unstructured":"FDA. Bioavailability and bioequivalence studies submitted in NDAs or INDs. Available from: https:\/\/www.fda.gov\/media\/88254\/download. Accessed June 10, 2024."},{"key":"ref12","unstructured":"EMA. Guideline on the investigation of bioequivalence. Available from: https:\/\/www.gmp-compliance.org\/files\/guidemgr\/2016_EMEA_Bioequivalence.pdf. Accessed June 10, 2024."},{"key":"ref13","unstructured":"FDA. Draft guidance on apremilast. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/Apremilast_Oral%20tablet_205437_RC09-15.pdf. Accessed September 18, 2015."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/cts.13013","volume":"14","author":"Huh","year":"2021","journal-title":"Clin Transl Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3109\/00498254.2011.604745","volume":"41","author":"Hoffmann","year":"2011","journal-title":"Xenobiotica"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/s0028-3908(98)00190-7","volume":"38","author":"Robichaud","year":"1999","journal-title":"Neuropharmacology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1517\/14656566.2015.1034107","volume":"16","author":"Abdulrahim","year":"2015","journal-title":"Expert Opin Pharmacother"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=100003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=100003","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T02:35:21Z","timestamp":1718332521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/pharmacokinetics-and-bioequivalence-of-apremilast-tablets-in-chinese-h-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":20,"URL":"https:\/\/doi.org\/10.2147\/dddt.s461771","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}